A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Hypertension is a global public health problem, and its prevalence is increasing worldwide. Impacting all human societies and socioeconomic strata, it remains the major modifiable risk factor for global burden of cardiovascular disease all-cause mortality and the leading cause of loss of disability-adjusted life years. Despite increased awareness, the rate of blood pressure control remains unsatisfactory, particularly in low- to middle-income countries. Apparent treatment-resistant hypertension is associated with worse adverse health outcomes. It includes both true resistant and pseudo-resistant hypertension, which requires out-of-office blood pressure monitoring to exclude white-coat effect and confirmation of adherence to the agreed recommended antihypertensive therapy. The depth of medication non-adherence remains poorly recognized among medical practitioners, thus presenting an underestimated modifiable risk factor. Medication non-adherence is a complex and multidimensional variable with three quantifiable phases: initiation, implementation, and discontinuation, collectively called persistence. Non-adherence can be both intentional and non-intentional and usually involves several interconnected factors. Persistence declines over time in the treatment of chronic diseases like hypertension. The risk is higher in patients with new diagnosis, poor insurance status, polypharmacy, and multiple comorbidities, particularly psychiatric disorders. The World Health Organization divides the contributing factors impacting adherence into five categories. Screening and detection for medication non-adherence are challenging due to its dynamic nature and potential white-coat effect. Easy-to-conduct screening methods have low reliability and validity, whereas more reliable and valid methods are costly and difficult to perform. Medication non-adherence is associated with poor clinical outcome and potential negative impact on health-care costs. Evaluation of adherence should become an integral part of assessment of patients treated for hypertension. Medication adherence can significantly improve with a patient-centered approach, non-judgmental communication skills, and collaborative multidisciplinary management, including engagement of the patients in their care by self-blood pressure monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting
Morisky, D. E., Ang, A., Krousel‐Wood, M., & Ward, H. J. (2008) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07572.x · Cited by 2,877 · cited 1×
“These methods tend to overestimate true adherence and correlate poorly with drug levels measured in urine samples.(46,47) Physicians’ perception of medication intake is subjective and generally inaccurate.”
BackgroundRetractedOsterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 1×
“It is important to differentiate true resistant from pseudo-resistant hypertension, because effective BP-lowering treatment with antihypertensives reduces BP-related morbidity and mortality.(13) Further, population-based studies show an increased risk of cardiovascular events, poor renal outcomes, and all-cause mortal…”
BackgroundMills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., & He, J. (2016) · Circulation · doi:10.1161/circulationaha.115.018912 · Cited by 3,531
A new taxonomy for describing and defining adherence to medications
Vrijens, B., De Geest, S., Hughes, D. A., Przemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04167.x · Cited by 2,028
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · cited 1×
“Respectively, patients with resistant hypertension are to be referred to as having apparent treatmentresistant hypertension (aTRH) because they include both true resistant and pseudo-resistant hypertensive individuals.(9) The term aTRH is used to identify “apparent” lack of blood pressure (BP) control on 3 or more med…”
BackgroundEconomic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900 · cited 1×
“These steps carry the risk of increased emergency department visits, leading to unnecessary hospitalizations and further increase in health-care costs.(62,63)”
BackgroundAdherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008
Egan, B. M., Zhao, Y., Axon, R. N., Brzezinski, W. A., & Ferdinand, K. C. (2011) · Circulation · doi:10.1161/circulationaha.111.030189 · Cited by 599
Tomaszewski, M., White, C., Patel, P., Masca, N., Damani, R., Hepworth, J., Samani, N. J., Gupta, P., Madira, W., Stanley, A., et al. (2014) · Heart · doi:10.1136/heartjnl-2013-305063 · Cited by 404 · cited 1×
“In this method, one can separate, identify, and quantify 40 most common antihypertensive medication and their metabolites.(55) It has very high specificity and sensitivity.”
MethodBetter compliance to antihypertensive medications reduces cardiovascular risk
Corrao, G., Parodi, A., Nicotra, F., Zambon, A., Merlino, L., Cesana, G., & Mancia, G. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328342ca97 · Cited by 367
Risk Factors for Nonadherence to Antihypertensive Treatment
Gupta, P., Patel, P., Štrauch, B., Lai, F. Y., Akbarov, A., Marešová, V., White, C. M. J., Petrák, O., Gulsin, G. S., Patel, V., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08729 · Cited by 256
Sim, J. J., Bhandari, S. K., Shi, J., Reynolds, K., Calhoun, D. A., Kalantar-Zadeh, K., & Jacobsen, S. J. (2015) · Kidney International · doi:10.1038/ki.2015.142 · Cited by 238 · cited 1×
“14,15”
Measuring, Analyzing, and Managing Drug Adherence in Resistant Hypertension
Burnier, M., Wuerzner, G., Struijker-Boudier, H., & Urquhart, J. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.00687 · Cited by 229
Frias, J., Virdi, N., Raja, P., Kim, Y., Savage, G., & Osterberg, L. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7833 · Cited by 213 · cited 1×
“57”
Berra, E., Azizi, M., Capron, A., Høieggen, A., Rabbia, F., Kjeldsen, S. E., Staessen, J. A., Wallemacq, P., & Persu, A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07464 · Cited by 195
Meddings, J., Kerr, E. A., Heisler, M., & Hofer, T. P. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-270 · Cited by 117 · cited 1×
“Patient interview requires physicians’ non-judgmental communication skills and can be no better than tossing a coin.(48) Pharmacy database records are not robust if not all pharmacies used by the patient are captured.”
BackgroundDrug adherence in hypertension: from methodological issues to cardiovascular outcomes
Hamdidouche, I., Jullien, V., Boutouyrie, P., Billaud, E., Azizi, M., & Laurent, S. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001299 · Cited by 111 · cited 1×
“Impact of Medication Non-Adherence on Health and Healthcare Costs Poor medication adherence has significant and multi-fold effects on the management of hypertension, increasing the risk of cardiovascular events, poor renal outcome, including end-stage kidney disease, and all-cause mortality.(58) Populationbased prospe…”
Background
Metadata
- Authors
- Hamrahian, S. M., Maarouf, O. H., & Fülöp, T.
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2022-10
- Volume
- Volume 16
- Pages
- 2749-2757
- ISSN
- 1177-889X (ISSN-L)
- OpenAlex
- W4302763418
- Cited by
- 170
- References
- 20
- FWCI
- 28.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.